Important Short Interest Filing: Is Cancer Genetics Incorporated (NASDAQ:CGIX) a Buy? The Stock Reported more Sellers

November 29, 2016 - By Winifred Garcia   ·   0 Comments

Important Short Interest Filing: Is Cancer Genetics Incorporated (NASDAQ:CGIX) a Buy? The Stock Reported more Sellers

The stock of Cancer Genetics Incorporated (NASDAQ:CGIX) registered an increase of 26.01% in short interest. CGIX’s total short interest was 305,700 shares in November as published by FINRA. Its up 26.01% from 242,600 shares, reported previously. With 99,600 shares average volume, it will take short sellers 3 days to cover their CGIX’s short positions. The short interest to Cancer Genetics Incorporated’s float is 2.47%. About 1,421 shares traded hands. Cancer Genetics Inc (NASDAQ:CGIX) has declined 44.44% since April 26, 2016 and is downtrending. It has underperformed by 49.70% the S&P500.

Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic services and products, and molecular markers. The company has a market cap of $28.54 million. The Firm develops, commercializes and provides molecular- and biomarker tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It currently has negative earnings. It has a range of disease-focused oncology testing portfolio.

Insitutional Activity: The institutional sentiment decreased to 0.73 in Q2 2016. Its down 0.77, from 1.5 in 2016Q1. The ratio dropped, as 6 funds sold all Cancer Genetics Inc shares owned while 4 reduced positions. 6 funds bought stakes while 9 increased positions. They now own 1.58 million shares or 24.74% more from 1.27 million shares in 2016Q1.
Morgan Stanley holds 0% of its portfolio in Cancer Genetics Inc (NASDAQ:CGIX) for 20,542 shares. Royal National Bank Of Canada holds 0% of its portfolio in Cancer Genetics Inc (NASDAQ:CGIX) for 97 shares. Citadel Advsrs Lc has 0% invested in the company for 14,979 shares. Pnc Financial Serv accumulated 21,000 shares or 0% of the stock. Eagle Glob Advsr Limited Liability Corp holds 84,320 shares or 0% of its portfolio. Manufacturers Life Insurance Commerce The accumulated 78 shares or 0% of the stock. Sabby Ltd holds 0.02% or 199,580 shares in its portfolio. Bankshares Of America Corporation De holds 0% or 569 shares in its portfolio. Renaissance Technology Lc holds 0% of its portfolio in Cancer Genetics Inc (NASDAQ:CGIX) for 101,200 shares. Goldman Sachs Gp owns 11,523 shares or 0% of their US portfolio. The Massachusetts-based Geode Management Ltd Co has invested 0% in Cancer Genetics Inc (NASDAQ:CGIX). The California-based Wells Fargo & Comm Mn has invested 0% in Cancer Genetics Inc (NASDAQ:CGIX). Diker Management Limited Liability Corp has 29,815 shares for 0.02% of their US portfolio. The New York-based Jpmorgan Chase And Communication has invested 0% in Cancer Genetics Inc (NASDAQ:CGIX). Beck Mack & Oliver Limited Liability Corporation holds 0% or 18,225 shares in its portfolio.

Insider Transactions: Since August 12, 2016, the stock had 4 insider buys, and 1 insider sale for $470,098 net activity. PAPPAJOHN JOHN had bought 31,100 shares worth $46,050 on Monday, November 14. $7,750 worth of Cancer Genetics Inc (NASDAQ:CGIX) was bought by Harris Geoffrey E.. 3,333 shares were sold by Sitar Edward J, worth $5,193 on Wednesday, November 16.

Cancer Genetics Inc (NASDAQ:CGIX) Ratings Coverage

Out of 3 analysts covering Cancer Genetics (NASDAQ:CGIX), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Cancer Genetics has been the topic of 3 analyst reports since March 11, 2016 according to StockzIntelligence Inc. Rodman & Renshaw initiated Cancer Genetics Inc (NASDAQ:CGIX) on Monday, September 26 with “Buy” rating. On Tuesday, March 15 the stock rating was maintained by Aegis Capital with “Buy”. The rating was downgraded by Janney Capital to “Neutral” on Friday, March 11.

CGIX Company Profile

Cancer Genetics, Inc., incorporated on April 8, 1999, is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic services and products and molecular markers. The Firm develops, commercializes and provides molecular- and biomarker tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It has a range of disease-focused oncology testing portfolio. The Company’s molecular- and biomarker diagnostic services are for three main sectors: cancer centers and hospitals, biotechnology and biopharmaceutical companies, and the research community. The Company’s services include clinical services, biopharma services and discovery services.

More notable recent Cancer Genetics Inc (NASDAQ:CGIX) news were published by: Globenewswire.com which released: “Cancer Genetics, Inc. to Present at the Dawson James Securities Growth Stock …” on October 14, 2016, also Globenewswire.com with their article: “Cancer Genetics, Inc. Ranked Among Fastest Growing Companies For Third …” published on November 16, 2016, Globenewswire.com published: “Cancer Genetics, Inc. Launches Focus::Renalâ„¢, a Unique, Comprehensive and …” on November 02, 2016. More interesting news about Cancer Genetics Inc (NASDAQ:CGIX) were released by: Globenewswire.com and their article: “Cancer Genetics Inc. Selected by H3 Biomedicine Inc., to Provide Biomarker …” published on July 18, 2016 as well as Seekingalpha.com‘s news article titled: “Cancer Genetics: ‘Warrant,’ You Are Under Arrest” with publication date: July 15, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Winifred Garcia

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>